Therapeutics News and Research

RSS

CytomX awarded $488,000 as grant under QTDP Program

CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).

12 Nov 2010

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the third quarter and the nine months ended September 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

12 Nov 2010

EntreMed reports $2.1 million net loss for third quarter 2010

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three- and nine-month periods ending September 30, 2010.

12 Nov 2010

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

Oligomerix, Inc. today announced the receipt of a two-year Small Business Innovation Research (SBIR) Phase II grant for $1.6M from the National Institute on Aging, National Institutes of Health (NIH), for a program to discover small molecules and antibodies targeting tau protein oligomers in the development of disease modifying therapeutics for Alzheimer's disease.

12 Nov 2010

NIH/NIDCR awards $1.1 million grant to Agenta for soft tissue healing development

Agenta Biotechnologies, Inc., a private biotechnology company, announced that it has received a $1.1 million grant from the National Institutes of Health and National Institute of Dental and Craniofacial Research (NIH/NIDCR) for the further development of a biologically activated membrane to improve soft tissue healing associated with oral surgery.

12 Nov 2010

Think treatments for cancer, diabetes don't grow on trees? Think again

Supported by thousands of years of use, a new wave of polymolecular botanical drugs (PBDs), backed by strong biomedical research and clinical trials, are growing in acceptance as a viable new drug category for the treatment and prevention of a wide spectrum of diseases from cancer to obesity.

11 Nov 2010

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the November 21 issue of BioWorld Today in the NewCo section.

11 Nov 2010

Novel mechanism regulating circadian rhythm identified

Scientists from the Florida campus of The Scripps Research Institute have identified for the first time a novel mechanism that regulates circadian rhythm, the master clock that controls the body's natural 24-hour physiological cycle. These new findings could provide a new target not only for jet lag, shift work, and sleep disturbances, but also for disorders that result from circadian rhythm disruption, including diabetes and obesity as well as some types of cancer.

11 Nov 2010

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

Scientists identify new way to drive dendritic cells from blood monocytes

Dendritic cells, known to be the prime movers of the body's immune response, are still notoriously difficult to study in humans. Samples, which come primarily from bone marrow or lymphoid tissue, are simply too difficult to obtain. But new research at Rockefeller University has shown scientists a way to study "authentic" dendritic cells from mouse monocytes, which are abundant in the blood, a much more accessible source in humans.

11 Nov 2010

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Hygeia Therapeutics, Inc. announced today the successful completion of a series of preclinical studies for HYG-102, their lead product for the treatment of vulvar and vaginal atrophy (VVA) and age-related skin fragility. HYG-102 is the lead biodegradable estrogenic candidate in a portfolio of 23 similar compounds licensed from the laboratory of Dr. Richard Hochberg of Yale University.

11 Nov 2010

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc. today announced that it will present a poster on Phase 2 results for AEZS-108 in advanced endometrial cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held at the Berlin Estrel Hotel and Convention Centre in Berlin, Germany November 16 through 19, 2010.

11 Nov 2010

Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment

Resolve Therapeutics, LLC today announced that it has entered into an exclusive license with the University of Washington for certain biologic compounds and technology developed to treat autoimmune diseases including systemic lupus erythematosus (SLE).

11 Nov 2010

Kylin receives $250,000 IRS award to advance pRNAi nanoparticle cancer treatment research

Officials of Kylin Therapeutics Inc. announces that they received a therapeutic discovery project grant from the U.S. Internal Revenue Service that will advance the company's pRNAi nanoparticle cancer treatment research.

11 Nov 2010

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.

10 Nov 2010

Repros third quarter net loss decreases to $1.2 million

Repros Therapeutics Inc. today announced financial results for the third quarter ended September 30, 2010 and provided an update on corporate actions.

10 Nov 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon, MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, in Atlanta, Georgia.

10 Nov 2010

Capstone Therapeutics third quarter net loss decreases to $2.6 million

Capstone Therapeutics, formerly OrthoLogic Corp.,, today announced financial results for the third quarter of 2010.

10 Nov 2010

Immunologix partners with Genscript to develop human antibody therapeutics

Immunologix, Inc, a Charleston, SC biotechnology company and a leader in fully human therapeutic antibodies for a variety of diseases and GenScript, a contract research organization (CRO) based in Piscataway, NJ and the industry leader in bio-reagent services, assay development & screening, lead optimization, and antibody drug development, announced today that the companies have formed a strategic partnership to offer a complete platform for producing human antibody therapeutics.

10 Nov 2010

Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation

Silence Therapeutics plc announces positive research findings demonstrating the ability of the Company's lead RNA interference (RNAi) drug candidate, Atu027, to prevent the formation of pulmonary metastasis in various animal models of cancer metastasis. Researchers showed that Atu027 inhibited multiple key biological processes that enable and contribute to the dissemination and formation of pulmonary metastases in a murine breast cancer metastasis model.

10 Nov 2010

Therapeutics News and Research

CytomX awarded $488,000 as grant under QTDP Program

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

EntreMed reports $2.1 million net loss for third quarter 2010

Oligomerix receives SBIR Phase II grant to develop drugs for Alzheimer’s disease

NIH/NIDCR awards $1.1 million grant to Agenta for soft tissue healing development

Think treatments for cancer, diabetes don't grow on trees? Think again

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

Novel mechanism regulating circadian rhythm identified

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Scientists identify new way to drive dendritic cells from blood monocytes

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment

Kylin receives $250,000 IRS award to advance pRNAi nanoparticle cancer treatment research

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Repros third quarter net loss decreases to $1.2 million

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Capstone Therapeutics third quarter net loss decreases to $2.6 million

Immunologix partners with Genscript to develop human antibody therapeutics

Silence Therapeutics' Atu027 RNAi drug prevents pulmonary metastasis formation

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News